What does CUSIP 61023L108 represent in this 13F holders report?

CUSIP 61023L108 is the security identifier for MNPR - MONOPAR THERAPEUTICS INC - COM used to aggregate holder disclosures.

How many institutions held MNPR - MONOPAR THERAPEUTICS INC - COM in Q3 2023?

14 institutional investors reported MNPR - MONOPAR THERAPEUTICS INC - COM for Q3 2023. Use the holders table for investor-level position and value details.

MONOPAR THERAPEUTICS INC - COM (MNPR)

CUSIP: 61023L108

Q3 2023 13F Holders as of 30 Sep 2023

Security type / class: Equity / COM
Total 13F shares: 301,390
Total 13F value: $182,200
Share change: +108,950
SEC-reported price per share: $0.62
Number of holders: 14
Value change: +$66,595
Number of buys: 7
Number of sells: 6

Security key

61023L108

Report period

Q3 2023

Institutions

Top holders

MNPR full security history Ownership snapshot Full 13F holder table Monopar Therapeutics SEC filings Monopar Therapeutics company facts Monopar Therapeutics 13D/G history

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of MNPR - MONOPAR THERAPEUTICS INC - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Andrew Paul Mazar

Disclosed value leader

Andrew Paul Mazar

Comparable rows

0/10

Latest evidence

30 Jun 2023

3/4/5 13F Highest disclosed value: $94,434 10 rows are not safely comparable across share classes. Showing 1-6 of 10 holder rows.

Quick read

Andrew Paul Mazar has the largest disclosed position value at $94.4K.

0 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Andrew Paul Mazar's linked filing trail.

Disclosed position value Top 5

Andrew Paul Mazar $94.4K

VANGUARD GROUP INC $84.8K

GEODE CAPITAL MANAGEMENT, LLC $35.8K

MILLENNIUM MANAGEMENT LLC $28K

Rappaport Reiches Capital Managem... $9.1K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 10 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Andrew Paul Mazar	3/4/5 Chief Scientific Officer, Director 3/4/5	— mixed-class rows	$94,434 277,584 shares mixed-class rows	—	31 Mar 2022
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$84,796 99,176 shares	—	30 Jun 2023
GEODE CAPITAL MANAGEMENT, LLC	13F Company 13F	— denominator unverified	$35,817 41,892 shares	—	30 Jun 2023
MILLENNIUM MANAGEMENT LLC	13F Company 13F	— denominator unverified	$28,011 32,761 shares	—	30 Jun 2023
Rappaport Reiches Capital Management, LLC	13F Company 13F	— denominator unverified	$9,144 10,695 shares	—	30 Jun 2023
MORGAN STANLEY	13F Company 13F	— denominator unverified	$3,420 4,000 shares	—	30 Jun 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

301,390

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders

Q3 2023 holders

Holder diff

Investor	Q2 2023 Shares	Q3 2023 Shares	Share Diff	Share Chg %	Q2 2023 value	Q3 2023 value	Value change	Value Chg %